LMHFDA Class 3 · implantable

Implant, Dermal, For Aesthetic Use

Device family · Unknown

Automated profile from regulatory + adverse-event registries · AI-reviewed · expert clinical sign-off in progress — not yet independently verified.
FDA clearances
1,028
Manufacturers
12
Flagged signals
40
Adverse-event reports
17,867

Code matrix

FDA product codeLMH
Device classClass 3
Regulation
GMDN— (crosswalk pending)
ImplantableYes
Life-sustainingNo

Adverse-event signals

Public · always free

MAUDE disproportionality (PRR), flagged where PRR ≥ 2, χ² ≥ 4, count ≥ 3.

Event typeYearReportsPRRχ²
Other20147665.14,006
Other201094429.339,689
20108307.52,136
Other20113221.7457
Other201110207.91,859
Other20108190.01,323
Other201260177.610,360
Other20114177.3537
Other20104177.3537
Other200928127.63,395
Other201143127.25,261
Other201342124.35,015
Other20135103.9412
Other20125103.9412
Other2014483.1248
Other2010468.2202
Other2013351.2102
Other20111750.3773
Other20115347.12,347
Other20145332.81,602
Other20103531.1990
Other20151029.6248
Other2011627.3127
Other2012926.6197
Other20122925.8666

Device-level recall linkage pending an FDA-recalls product-code re-ingest. Class 3 family · 17,867 total adverse-event reports.

Manufacturer landscape

ManufacturerClearancesLatestConcern
MERZ NORTH AMERICA, INC.3732026
Q-Med AB2482026
Allergan2402025
Teoxane S.A.512026
Tiger Aesthetics Medical, LLC422025
Prollenium Medical Technologies, Inc.232025
Anika Therapeutics, Inc.202015
Genzyme Biosurgery152014
Colbar Lifescience , Ltd.52009
Mentor Corp.51991
SYMATESE52026
CROMA-PHARMA GmbH12025

Concern score lights up where a maker maps to a scored entity (depth fast-follow).

Recent FDA clearances

SCULPTRA AND SCULPTRA AESTHETIC · Q-Med ABPMA · 2026-04-15
Restylane® Refyne, Restylane® Defyne, Restylane® Kysse and Restylane® Contour · Q-Med ABPMA · 2026-04-14
RHA 2, RHA 3, RHA 4 · Teoxane S.A.PMA · 2026-04-07
RHA® Redensity, RHA® Redensity™ Mepi, RHA®2 and RHA®2 Mepi, RHA®3 and RHA®3 Mepi, RHA®4 and RHA® Dynamic Volume · Teoxane S.A.PMA · 2026-04-01
RHA® Redensity™ Mepi (also called RHA®1 Mepi), RHA®2 Mepi, RHA®3 Mepi, RHA® Dynamic Volume (formerly called RHA®4 Mepi) · Teoxane S.A.PMA · 2026-03-31
RADIESSE® Injectable Implant · Merz North America, Inc.PMA · 2026-03-31
RADIESSE® Injectable Implant · Merz North America, Inc.PMA · 2026-03-24
RADIESSE® Injectable Implant · Merz North America, Inc.PMA · 2026-03-24
P050052 RADIESSE® Injectable Implant; RADIESSE® Hands; RADIESSE® (+) Lidocaine; Jawline indication · Merz North America, Inc.PMA · 2026-03-24
RADIESSE® Injectable Implant · Merz North America, Inc.PMA · 2026-03-24
Restylane® Contour · Q-Med ABPMA · 2026-03-20
RADIESSE® Injectable Implant · Merz North America, Inc.PMA · 2026-03-18
RADIESSE® Injectable Implant · Merz North America, Inc.PMA · 2026-03-18
RESTYLANE INJECTABLE GEL · Q-Med ABPMA · 2026-03-12
Evolysse™ Smooth; Evolysse™ Form · SymatesePMA · 2026-02-27
Restylane Lyft with Lidocaine · Q-Med ABPMA · 2026-02-05
Restylane®-L 1 mL; Restylane® Lyft™ with Lidocaine 1 mL; Restylane® Eyelight™ 0.5 mL · Q-Med ABPMA · 2026-01-29
RHA® Redensity dermal filler · Teoxane S.A.PMA · 2026-01-14
RADIESSE® Injectable Implant · Merz North America, Inc.PMA · 2026-01-13
RADIESSE® Injectable Implant, RADIESSE® Hands, RADIESSE® (+) Lidocaine, Jawline indication · Merz North America, Inc.PMA · 2026-01-13
Restylane® Lyft with Lidocaine · Q-Med ABPMA · 2025-12-23
Revanesse Versa; Revanesse Versa+ (with lidocaine); Revanesse Lips+ (with lidocaine) · Prollenium Medical Technologies, Inc.PMA · 2025-12-22
Evolysse Injectable Hyaluronic Acid · SymatesePMA · 2025-12-19
Evolysse® FORM · SymatesePMA · 2025-12-18
RADIESSE INJECTABLE IMPLANT · Merz North America, Inc.PMA · 2025-12-12

Sources: FDA 510(k)/PMA · openFDA MAUDE · FDA device classification · MedevIQ manufacturer-canonical. Registry data, AI-reviewed; expert clinical sign-off in progress.

Early access

MedevIQ is in private preview.

We're onboarding hospitals, manufacturers, regulators and research teams in waves. Tell us how you'd use MedevIQ and we'll get back within a working week.

We'll reply within a working week.

Access by invitation while v1 finalizes.